Finance
US FDA approves Sanofi's bleeding disorder therapy
Published by Global Banking & Finance Review®
Posted on March 28, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 28, 2025
1 min readLast updated: January 24, 2026
The FDA has approved Sanofi's therapy for a rare bleeding disorder, offering a new treatment for patients aged 12 and older.
(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.
(Reporting by Padmanabhan Ananthan and Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
The main topic is the FDA's approval of Sanofi's new therapy for a rare bleeding disorder.
The therapy is intended for patients aged 12 and older with a rare bleeding disorder.
This approval is significant as it introduces a novel treatment option for a rare condition.
Explore more articles in the Finance category
